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I. Introduction
QT interval on the surface electrocardiogram (ECG) is the 
period from depolarization to repolarization of ventricle, 
and QT interval can be calculated in the ECG by measur-
ing the distance between the start of the Q wave and the end 
of the T wave. Prolongation of the QT interval is known to 
possibly cause ventricular arrhythmia, including tachycar-
dia, fibrillation, and torsades de pointes (TdP), resulting in 
syncope or sudden death [1-3]. Because of fatal outcome, 
the possibility of QT prolongation has been a very impor-
tant issue. Many non-cardiovascular drugs are suspected 
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Objective: The aim of this study was to examine whether or not levofloxacin has any relationship with QT prolongation in 
a real clinical setting by analyzing a clinical data warehouse of data collected from different hospital information systems. 
Methods: Electronic prescription data and medical charts from 3 different hospitals spanning the past 9 years were reviewed, 
and a clinical data warehouse was constructed. Patients who were both administrated levofloxacin and given electrocar-
diograms (ECG) were selected. The correlations between various patient characteristics, concomitant drugs, corrected QT 
(QTc) prolongation, and the interval difference in QTc before and after levofloxacin administration were analyzed. Results: 
A total of 2,176 patients from 3 different hospitals were included in the study. QTc prolongation was found in 364 patients 
(16.7%). The study revealed that age (OR 1.026, p < 0.001), gender (OR 0.676, p = 0.007), body temperature (OR 1.267, p = 
0.024), and cigarette smoking (OR 1.641, p = 0.022) were related with QTc prolongation. After adjusting for related factors, 
12 drugs concomitant with levofloxacin were associated with QTc prolongation. For patients who took ECGs before and after 
administration of levofloxacin during their hospitalization (n = 112), there was no significant difference in QTc prolongation. 
Conclusions: The age, gender, body temperature, cigarette smoking and various concomitant drugs might be related with 
QTc prolongation. However, there was no definite causal relationship or interaction between levofloxacin and QTc prolonga-
tion. Alternative surveillance methods utilizing the massive accumulation of electronic medical data seem to be essential to 
adverse drug reaction surveillance in future.
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to cause QT prolongation. They include some antidepres-
sants (amitriptyline, fluoxetine, doxepine, venlafaxine, etc.), 
antimicrobials (azithromycin, levofloxacin, roxithromycin, 
etc.), antihistamines (astemizole, clemastine, etc.), antipsy-
chotics (clozapine, quetiapine, sultopoide, etc.) and so on [1, 
4-6]. There have been label changes or market withdrawal of 
drugs found to carry high risk of QT prolongation [3,7], and 
these drugs include terfenadine, astemizole, grepafloxacin, 
terodiline, droperidol, lidoflazine, sertindole, levomethadyl, 
and cisapride.
  The reports of adverse drug reaction (ADR) during pre-
marketing clinical trials are very limited, because of limi-
tation of the number of subjects, clinical setting and age 
groups. For example, phase 3 clinical trials are usually per-
formed with only 1,000 to 3,000 subjects, and children, old 
and pregnant women are usually excluded from the studies 
[8]. Therefore, the monitoring of safety of drugs after mar-
keting is mandatory to find any harmful reactions that were 
not observed prior to approval. The safety of drugs after 
marketing is continuously monitored through epidemiologic 
studies, such as spontaneous report, chart review, cohort 
study and case report [9]. Some drugs, such as cisapride, ce-
lecoxib and rofecoxib were withdrawed from the market due 
to fatal ADRs, even though they showed no noticeable ADRs 
in clinical trials [10].
  Recently, the electronic medical record (EMR) and com-
puterized physician order entry (CPOE) system adoption 
rate has been ever increasing [11,12]. As a result, there are 
many efforts to use EMR and CPOE data for the capture of 
ADR [13]. Use of data warehouse in clinical areas has also 
been reported [14,15]. Data warehouse (DW) is a database 
repository for the analytical purposes from the operational 
database. Szirbik et al. [16] suggests a general method for 
constructing a clinical DW. Sheen et al. [17] reported that 
overdose rate in patients with moderate to severe renal in-
sufficiency was 28.2%, when tertiary teaching hospital’s 4 
years prescription data in a DW were analyzed. Zhang et 
al. [15] analyzed clinical prescription data in a DW and re-
ported that concomitant administration of aminoglycoside 
and cephalosporin increased nephrotoxicity, and Hinrichsen 
et al. [18] constructed an electronic vaccine adverse reaction 
reporting system that was interfaced to the EMR system, and 
found 6-fold increase in vaccine adverse reaction reports 
compared to traditional self reporting method. 
  Levofloxacin, an antibiotic of the fluoroquinolone drug 
class had been reported to cause QT prolongation in animal 
studies [19]. There have been several reports that levofloxa-
cin is associated with corrected QT (QTc) prolongation [20-
22]. However, some study has reported that there is no effect 
of levofloxacin on QTc prolongation [23]. Therefore, the 
effect of levofloxacin on QTc prolongation remains still con-
troversial.
  This study aims to examine whether levofloxacin has any 
relation with QT prolongation in real clinical setting by us-
ing a clinical DW, which contained past 9 years electronic 
prescription data from 3 different general hospitals. We 
analyzed the relationship between epidemiologic and clini-
cal characteristics of the subjects with QT prolongation. The 
relationship between the concomitant drugs with levofloxa-
cin and QT prolongation was analyzed, after adjusting epide-
miologic and clinical characteristics of the subjects. Finally, 
the difference in QT prolongation between pre- and post-
administration of levofloxacin was analyzed.
II. Methods
1. Data Preparation and Study Population
Three hospitals joined in this study. A hospital is a 1,089-bed 
tertiary teaching hospital, B hospital is a 1,198-bed tertiary 
teaching hospital, and C hospital is a 131-bed general hos-
pital. The study period ranged 9 years for A hospital (1998-
2006), and 5 years for B and C hospitals (2002-2006).This 
study was reviewed and approved by the Institutional review 
board committees.
  The method how to make data mart for this study was 
partly introduced in the previous work in detail [24]. Briefly, 
patients who were administrated subject drug (levofloxacin) 
during their hospitalization within the period mentioned 
above were selected. Then, every prescription and ECG 
examination data on patients who were selected was trans-
formed and loaded into a data base (MS-SQL 2000, Micro-
soft, USA). The resulting data included 136,146 levofloxacin 
prescriptions for 21,950 patients. Of patients who were ad-
ministrated levofloxacin and whose ECG was taken during 
the hospitalization, only patients whose age was 18 years or 
older were selected (n = 3,854) (Figure 1).
  Patients’ epidemiologic and clinical data were collected by 
manually reviewing the available medical charts (n = 2,903). 
The epidemiologic and clinical data included age, gender, 
height, body weight, blood pressure, body temperature, heart 
rate, body mass index (BMI), cigarette smoking, alcohol 
drinking, presence of chronic disease (hypertension, diabe-
tes, hepatitis, and tuberculosis), final discharge diagnoses, 
operation and treatment procedures. ECG results were also 
reviewed manually. By reviewing the discharge summery, 
one main discharge diagnosis and associate diagnoses up to 
10, surgical and treatment procedures up to 7 were exam-
ined. De-identification of patients’ personal data was per-60 doi: 10.4258/hir.2011.17.1.58 www.e-hir.org
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formed prior to analysis.
  For the QTc measurement of hospital A, it was automati-
cally calculated by the ECG device using Bazett's formula 
[25]. Because the QTc was not available from the ECG de-
vice, the QT value was manually measured and then QTc 
was calculated using Bazett's formula for 2 other hospitals (B, 
C hospital).
  Patients with disease that directly affects ECG wave and 
QT, such as ischemic heart disease, heart failure, myocardi-
tis, mitral valve prolapsed, atrial fibrillation, cerebrovascular 
disease, rheumatic fever, anorexia nervosa, starvation, hypo-
thyroidism, hypomagnesemia or renal failure, were excluded 
from the study (n = 645). Patients with unreliable QTc in 
ECG due to base-line swing, base-line noise, T-inversion, flat 
T wave, U-wave, irregular RR interval, premature ventricu-
lar contracture due to myocarditis, myocardial infarction, 
heart failure, pericarditis, atrial fibrillation and coronary ar-
teriosclerosis were also excluded (n = 82). The resulting total 
number of subjects for the study was 2,176 (M = 1,316, F = 
860).
  Of 2,176 subjects, 588 patients were selected for the analysis 
of effects of other concomitant drugs with levofloxacin on 
QTc prolongation. Concomitant drugs that were 50 times or 
more frequently prescribed were selected. Multiple logistic 
regression for each drug was performed after adjusting the 
effect of epidemiologic and clinical variables.
  On the case-series study design, difference in QTc prolon-
gation before and after levofloxacin administration was ana-
lyzed. Patients who had both records on ECG examination 
before and after levofloxacin were selected (n = 112). It was 
regarded as ‘pre-levofloxacin administration’ when a patient 
was not administrated levofloxacin more than 2 days before 
ECG examination. On the other hand, it was considered as 
‘post-levofloxacin administration’ when levofloxacin admin-
istrated and ECG examination occurred on the same day.
2. Definition of QTc Prolongation
For QTc interval prolongation standards in terms of gender 
classification, the QTc interval prolongation for men was set 
at QTc > 450 msec (normal 430 msec + borderline 20 msec), 
and QTc > 470 msec for women (normal 450 msec + border-
line 20 msec) [26].
3. Statistical Analysis
Mann-Whitney and chi-square test were performed to 
examine the difference in QTc prolongation by clinical or 
Figure 1. Case selection process and 
scope of the study. A data 
warehouse, which contains 
electronic prescription data 
from 3 different general hos-
pitals, were constructed. 
Total of 2,176 patients were 
selected for the ana  ly  ses. 
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epidemiologic characteristics of patients. Then multiple 
logistic regression was performed with the previous major 
factors affecting QTc prolongation. To reveal the effects of 
other concomitant drugs with levofloxacin on QTc, mul-
tiple logistic regression was performed after adjusting major 
clinical and epidemiologic factors. Wilcoxon signed rank 
test was performed in order to determine whether there was 
difference in QTc prolongation before and after levofloxacin 
administration. SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA) 
was used for the analyses.
III. Results
The analysis showed mean age of 52.5 years (52.7 ± 17.1 for 
men, 52.3 ± 17.9 for women), mean height of 163.7 cm (168.7 
± 6.5 for men, 156.0 ± 6.7 for women), mean body weight of 
60.8 kg (64.5 ± 11.2 for men, 55.0 ± 10.0 for women), mean 
BMI of 22.6 kg/m
2 (22.6 ± 3.4 for men, 22.6 ± 3.8 for wom-
en), mean systolic blood pressure of 119.2 mmHg (120.0 ± 
16.8 for men, 117.9 ± 18.1 for women), mean diastolic blood 
pressure of 74.5 mmHg (75.0 ± 11.4 for men, 73.7 ± 11.1 for 
women), mean body temperature of 36.7
oC (36.7 ± 0.62 for 
men, 36.7 ± 0.64 for women), mean heart rate of 80.9 beats/
min (80.2 ± 19.2 for men, 81.9 ± 17.5 for women), and mean 
QTc interval of 423.3 msec (420.7 ± 39.3 for men, 427.2 ± 
39.0 for women) (Table 1).
1. Association of Patients’ Characteristics with QTc
QTc prolongation was found in 256 (19.4%) out of 1,316 for 
men and 108 (12.6%) out of 860 for women who had been 
administrated levofloxacin during their hospitalization. 
There was difference in QTc prolongation by age for men 
and women (p < 0.001), height for women (p < 0.001), body 
weight for men (p = 0.001), BMI for men (p = 0.018), systolic 
blood pressure (p = 0.013), body temperature for men (p = 
0.009), heart rate for both (p < 0.001), cigarette smoking for 
men (p = 0.016) and alcohol drinking for men (p = 0.057) at 
a significance level of 0.1 (Table 2). 
  With these variables, forward stepwise multiple logistic 
regression analysis revealed that age (p < 0.001), gender (p = 
0.007), body temperature (p = 0.024) and cigarette smoking 
(p = 0.022) were associated with QTc prolongation (Table 3).
2. Association of Concomitant Drugs with QTc
Of 720 drugs jointly administered with levofloxacin, 32 
drugs that were prescribed 50 times or more frequently were 
selected (Table 4). 
  Chi-square test revealed that 18 drugs were associated with 
QTc prolongation at the significance level of 0.1. The logistic 
regression revealed that the following drugs were associated 
with QTc prolongation, even after adjusting the effect of 
major variables (age, gender, body temperature and cigarette 
smoking): furosemide (odd ratio [OR], 5.8; p < 0.001), mag-
nesium sulfate (OR, 7.8; p < 0.001), propacetamol (OR, 4.1; p 
< 0.001), sucralfate (OR, 2.5; p = 0.019), aminophylline (OR, 
2.6; p = 0.004), vecuronium bromide (OR, 6.0; p < 0.001), 
heparin sodium (OR, 3.7; p = 0.014), human serum albumin 
(OR, 3.8; p < 0.001), isosorbide dinitrate (OR, 4.6; p = 0.003), 
morphine (OR, 4.4; p < 0.001), clindamycin (OR, 4.9; p < 
0.001), and amikacin sulfate (OR, 3.0; p = 0.004) (Table5).
3. Difference in QTc after Levofloxacin Administration
Patients who took ECGs before and after administration of 
levofloxacin during their hospitalization were selected from 
the clinical data mart. The Wilcoxon signed rank test was 
performed on the patients extracted to determine whether 
there was QTc interval differences between pre and post le-
vofloxacin administration (Table 6).
  There were total 112 pre and post comparable patients 
(con  sisting of 76 males [67.9%], and 36 females [32.1%]). 
The pre levofloxacin administration QTc mean was 432.9 
msec (± 36.8), while the post QTc mean was 434.5 msec (± 
33.3). Seventy-seven patients (68.8%) were ‘Normal to Nor-
mal,’ 12 patients (10.7%) were ‘Normal to Prolonged,’ 10 
patients (11.6%) were ‘Prolonged to Normal,’ and 13 patients 
(11.6%) were ‘Prolonged to Prolonged.’ Wilcoxon signed 
rank test revealed that there was no statistically significant 
QTc prolongation difference between pre and post levofloxa-
Table 1. Characteristics of the study population (n = 2,176)
Male 
(n = 1,316) 
Female 
(n = 860) 
p-value
Age   52.7 ± 17.1  52.3 ± 17.9 0.563
Height (cm) 168.7 ± 6.5 156.0 ± 6.7 <0.001
Body weight (kg)   64.5 ± 11.2  55.0 ± 10.0 <0.001
Body mass index (kg/m
2) 22.6 ± 3.4   22.6 ± 3.8 0.896
Systolic blood pressure 
  (mmHg)
120.0 ± 16.8 117.9 ± 18.1 0.006
Diastolic blood pressure 
  (mmHg)
  75.0 ± 11.4   73.7 ± 11.1 0.006
Body temperature (
oC)  36.7 ± 0.62   36.7 ± 0.64 0.789
Heart rate (beats/min)  80.2 ± 19.2   81.9 ± 17.5 0.330
QTc interval (msec) 420.7 ± 39.3 427.2 ± 39.0 <0.001
Values are presented as mean ± SD. 
QTc: corrected QT interval, SD: standard deviation.62 doi: 10.4258/hir.2011.17.1.58 www.e-hir.org
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cin administration (p = 0.353).
IV. Discussion
1. Main Findings
The study revealed that age, gender, body temperature and 
cigarette smoking are related with QTc interval prolongation. 
This result is consistent with previous studies indicating that 
QTc is related with age, gender, body temperature [27] and 
cigarette smoking [28].
  Even after adjusting the major factors, 12 drug types still 
showed significant correlation. However, because of the 
limitation of study design, it is not clear whether such cor-
relations are caused by any interaction, or by associated 
conditions or by concomitant drugs itself. Furosemide and 
clindamycin have already been known to be related with 
QTc prolongation [3]. Isosorbide dinitrate is usually used 
in angina pectoris, which is related with QT interval change 
[29]. Morphine is a strong pain-killer used to relieve pain 
after surgery or cancer pain, and it is likely that it has a cor-
relation to QTc prolongation in diverse situations where it 
must be administered. Vecuronium bromide is a drug used 
Table 2. Comparison of study populations’ characteristics by QTc
Continuous variables
QTc for men
a
p-value
b
QTc for women
a
p-value
b Normal 
(n = 1,060)
Prolonged 
(n = 256)
Normal 
(n = 752)
Prolonged 
(n = 108)
Age (yr)      51.4 ± 17.1      58.3 ± 16.2 <0.001      50.8 ± 17.9      62.3 ± 14.6 <0.001
Height (m) 168.9 ± 6.5 167.9 ± 6.8   0.111 156.3 ± 6.6 153.6 ± 6.6 <0.001
Body weight (kg)     65.1 ± 11.2     62.0 ± 10.6 <0.001     55.2 ± 10.1   53.2 ± 9.3   0.118
Body mass index (kg/m
2)   22.7 ± 3.4   22.1 ± 3.3   0.018   22.6 ± 3.9   22.5 ± 3.5   0.904
Systolic pressure (mmHg)   119.7 ± 16.0   121.5 ± 19.8   0.388   117.2 ± 17.6   122.7 ± 20.5   0.100
Diastolic pressure (mmHg)     75.2 ± 11.2     74.5 ± 12.2   0.302     73.6 ± 11.1     74.1 ± 10.9   0.348
Body temperature (
oC)   36.7 ± 0.6   36.7 ± 0.7   0.009    36.7 ± 0.6   36.7 ± 0.7   0.586
Heart rate (beats/min)     77.7 ± 17.9     91.0 ± 20.5 <0.001     80.8 ± 17.1     89.7 ± 18.7 <0.001
QTc interval (msec)   406.6 ± 26.4   479.1 ± 28.9 <0.001   417.1 ± 28.5   498.0 ± 27.7 <0.001
Categorical variables
No. of QTc for men
p-value
c No. of QTc for women
p-value
c
Normal Prolonged Normal Prolonged
Cigarette smoking No 951 216  0.016 718 102  0.413
Yes 100   38   25      5
Alcohol drinking No 972 225  0.057 726 105  1.000
Yes    80    29   17     2
Diabetes No 962 227  0.327 669   93  0.311
Yes    90   27   74   14
Hypertension No 940 221  0.316 651   90 0.352  
Yes 112   33   92   17
Tuberculosis No 946 220  0.141 662   90  0.142
Yes 106   34   80    17
Hepatitis No 1,041 253  0.480 731 104  0.420
Yes   11     1   12   3
QTc: corrected QT interval, SD: standard deviation.
aValues are presented as mean ± SD. 
bMann-Whitney test. 
cChi-square test. 
Table 3. Association of factors with QTc prolongation
OR 95% CI p-value
Age (yr) 1.026 1.017-1.034 <0.001
Gender (female) 0.676 0.509-0.899   0.007
Body temperature (
oC) 1.267 1.031-1.555   0.024
Cigarette smoking 1.641 1.076-2.503   0.022
OR: odds ratio, CI: confidence interval.63 Vol. 17  •  No. 1  •  March 2011 www.e-hir.org
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to relax muscles during operations. According to the study 
by Radhakrishnan et al. [30] there has been cases of QT 
interval prolongation in patients due to heparin-induced 
hypocalcaemia. Magnesium sulfate is known to be effective 
in the treatment of ventricular arrhythmias. However, there 
still lack reports of correlation between QT prolongation and 
aminophylline, propacetamol, sucralfate, and amikacin sul-
fate. Individual drug itself or joint administration of different 
drugs may be related with QTc prolongation or the clinical 
Table 4. Association of concomitant drugs with QTc prolongation 
in combination with levofloxacin
Drug
Drug 
administration
No. of QTc
p-value
a
Normal Prolonged
Tramadol - 353 79 0.753
+ 125 31
Furosemide - 440 78 <0.001
+ 38 32
Acetylcysteine - 389 72 <0.001
+ 89 38
Ketorolac - 374 87 0.947
  tromethamine + 104 23
Cimetidine - 408 87 0.139
+ 70 23
Pethidine - 383 92 0.479
+ 95 18
Ranitidine - 438 92 0.018
+ 40 18
Pancreatine - 407 94 1.000
+ 71 16
Metoclopramide - 412 95 1.000
+ 66 15
Magnesium
  sulfate
- 459 86 <0.001
+ 19 24
Propacetamol - 440 86 <0.001
+ 38 24
Bromhexine - 443 90 0.001
+ 35 20
Sucralfate - 457 96 0.002
+ 21 14
Aminophylline - 448 86 <0.001
+ 30 24
Vecuronium
  bromide
- 460 85 <0.001
+ 18 25
Heparin sodium - 466 102 0.028
+ 12 8
Human serum 
  albumin 
- 455 89 <0.001
+ 23 21
Tranexamic acid - 428 103 0.258
+ 50 7
Isosorbide
  dinitrate
- 470 99 <0.001
+ 8 11
Table 4. Continued
Drug
Drug 
administration
No. of QTc
p-value
a
Normal Prolonged
Morphine - 457 88 <0.001
+ 21 22
Isoniazide - 423 101 0.401
+ 55 9
Clindamycin - 453 87 <0.001
+ 25 23
Codeine
 phosphate
- 438 99 0.719
+ 40 11
Itraconazole - 423 99 0.777
+ 55 11
Digoxin - 475 105 0.006
+ 3 5
Tiropramide - 453 106 0.651
+ 25 4
Roxatidine
  acetate
- 464 103 0.143
+ 14 7
Amlodipine
 besylate
- 462 100 0.017
+ 16 10
Atrophine
  sulfate
- 477 110 1.000
+ 1 0
Amikacin
  sulfate
- 453 97 0.02
+ 25 13
Caroverine - 429 105 0.092
+ 49 5
Prednisolone - 455 101 0.241
+ 23 9
QTc: corrected QT interval. 
aChi-square test.64 doi: 10.4258/hir.2011.17.1.58 www.e-hir.org
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condition in which the relevant drugs administered can also 
be related with the QTc prolongation. Nykamp et al. [20] has 
studied on QTc prolongation associated with levofloxacin. 
He concluded that the use of levofloxacin alone may cause 
QT interval prolongation. Further study is needed for more 
reasonable explanation.
  One of the essential points of this study was to develop and 
discover research methods utilizing heavily accumulating 
medical data in electronic form. EMR and CPOE systems 
are fast adopted by many hospitals [11,12]. However, the use 
of data warehouse or data mart in the field of post-market 
surveillance (PMS) is in its early stage. At present, much of 
actual clinical electronic databases are created within the 
hospitals, nevertheless, most of the clinically important pa-
tient information are records on paper or non-standardized 
data on the electronic database. Consequently, therefore, 
the information had to be obtained manually. Integrating 
electronic medical data from different hospitals is a difficult, 
tedious and multistep process not only in terms of technical 
problems of integrating heterogeneous database schema, but 
also problems of institutional policies, privacy and secu-
rity problems. The detailed processes of data warehouse or 
data mart construction have been reported elsewhere [24]. 
Although massive data-driven analysis, such as the present 
study, has not been described to explain a causal relationship 
compared to well-designed clinical trial, nonetheless, it can 
be useful to get a simple and quick insight into a problem.
2. Limitations
The present results carry several limitations. As a retrospec-
tive study on general in-patients, major confounding factors 
could not be pre-adjusted, and details of diseases for hospital 
admission, base disease, major history, various drug admin-
istration and treatments while in hospital are heterogeneous. 
Taking these limitations into account, the major clinical 
indicators of subjects (age, gender, body temperature, ciga-
rette smoking) were adjusted during the analysis process, 
but limitations may still be inherent. As a study just on the 
exposed group to levofloxacin without a control group, the 
relationship between cause and result could not be exam-
ined. As a retrospective study, this research was dependent 
mainly on the records in relation to the measurement of 
major variables, therefore adequate management of mea-
surement accuracy and precision could not be evaluated. 
Moreover, systematic measurement errors of the participat-
ing institution could also exist. For example, there are many 
types of ECG devices which would be different for each 
department and hospital. Because the types of ECG devices 
are different between hospitals and some may even be using 
non-automated ECG devices, there could be inter-observer 
and intra-observer variability when manually measuring QT 
interval. Because the conditions of patients were so diverse, 
and representative diagnosis and ECG values were selected, 
thus giving rise to some variation in the information.
  In this study, subjects who had heart diseases according to 
the main-diagnosis and sub-diagnosis records were excluded 
from the study population. However, drugs for cardiovascu-
lar diseases were found in the concomitant drugs. It seems 
that the discharge diagnoses of patients may not in some 
Table 5. Association of concomitant drugs with QTc prolonga-
tion in combination with levofloxacin, after adjusting 
the major variables: age, gender, body temperature and 
cigarette smoking
Drug OR 95% CI p-value
Furosemide 5.8   3.2-10.4 <0.001
Magnesium sulfate 7.8   3.7-16.4 <0.001
Propacetamol 4.1    2-7.6 <0.001
Sucralfate 2.5 1.2-5.3   0.019
Aminophylline 2.6 1.4-4.9   0.004
Vecuronium bromide 6.0   3.0-11.9 <0.001
Heparin sodium 3.7   1.3-10.7   0.014
Human serum albumin 3.8 1.9-7.6 <0.001
Isosorbide dinitrate 4.6   1.7-12.6   0.003
Morphine 4.4 2.2-8.8 <0.001
Clindamycin 4.9 2.5-9.5 <0.001
Amikacin sulfate 3.0 1.4-6.5   0.004
OR: odds ratio, CI: confidence interval.
Table 6. Comparison of QTc between before and after levofloxa-
cin administration
QTc (before → after) Male Female Total (%)
Normal → Normal 51 26   77 (68.8)
Normal → Prolonged   8   4   12 (10.7)
Prolonged → Normal   5   5 10 (8.9)
Prolonged → Prolonged 12   1   13 (11.6)
Total 76 36  112 (100.0)
Mean QTc
  (msec)
Before 428.8 
(± 30.1)
441.6 
(± 47.3)
432.9 
(± 36.8)
After 434.7 
(± 35.3)
434.0 
(± 29.2)
434.5 
(± 33.3)
p-value
a 0.186 0.802 0.353
QTc: corrected QT interval. 
aWilcoxon signed rank test. 65 Vol. 17  •  No. 1  •  March 2011 www.e-hir.org
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cases be representative for the present illness.
  There was no statistically significant difference in QTc 
pro  longation between before and after administration of 
levo  floxacin. However, significance may not be clear in this 
massive data-driven study, because of heterogeneous nature 
of the data set obtained from real clinical environments. For 
definite analysis, a more sophisticated clinical data mart for 
PMS would be helpful. We are in a process to construct a 
more well-designed clinical data mart for PMS.
  Although we performed this study to identify possible as-
sociation between levofloxacin and QTc prolongation, a lot 
of time and extensive labor was consumed due to required 
many manual processes. A well designed database-driven 
approach, analyzing the drug-ADR of EMR databases such 
as comparison of exposed and non-exposed group for a drug 
with automated process which not need any intervention of 
specialist, seems essential to identify ADR signals quickly. 
We are preparing an automated ADR signal detection algo-
rithm and system.
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